Patents by Inventor Mark A. Paulik

Mark A. Paulik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12084485
    Abstract: This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 10, 2024
    Assignee: I2O Therapeutics, Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark Paulik
  • Publication number: 20240239861
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 18, 2024
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 11840559
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: December 12, 2023
    Assignee: i2o Therapeutics, Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Publication number: 20230063420
    Abstract: This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: December 16, 2021
    Publication date: March 2, 2023
    Inventors: William Blackwell, Ved P. Srivastava, Mark Paulik
  • Publication number: 20220332781
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: November 30, 2021
    Publication date: October 20, 2022
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 11214607
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 4, 2022
    Assignee: Intarcia Therapeutics Inc.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Publication number: 20200299350
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: October 29, 2019
    Publication date: September 24, 2020
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Patent number: 10501517
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 10, 2019
    Assignee: INTARCIA THERAPEUTICS, INC.
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young, Robert Neil Hunter, III, Steven Thomas Dock
  • Publication number: 20180009871
    Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
    Type: Application
    Filed: May 15, 2017
    Publication date: January 11, 2018
    Inventors: William Blackwell, Ved P. Srivastava, Mark A. Paulik, Andrew Young
  • Patent number: D779544
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 21, 2017
    Assignee: Gamblit Gaming, LLC
    Inventor: Mark Paulik
  • Patent number: D781340
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: March 14, 2017
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Mark Paulik, Brian Erice, Zach Foley
  • Patent number: D801376
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: October 31, 2017
    Assignee: Gamblit Gaming, LLC
    Inventor: Mark Paulik
  • Patent number: D823888
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: July 24, 2018
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Timothy Isaacson, Zachary Foley, Mark Paulik, Michael Splitz
  • Patent number: D849771
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: May 28, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Zachary Foley, Mark Paulik, Edvard Toth
  • Patent number: D849772
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 28, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Mark Paulik, Brian Erice
  • Patent number: D851662
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: June 18, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Mark Paulik, Brian Erice, Zachary Foley
  • Patent number: D852810
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 2, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Zachary Foley, Mark Paulik, Brian Erice
  • Patent number: D854554
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 23, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Edvard Toth, Zachary Foley, Mark Paulik, Brian Erice
  • Patent number: D860240
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: September 17, 2019
    Assignee: gamblit Gaming, LLC
    Inventor: Mark Paulik
  • Patent number: D868825
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: December 3, 2019
    Assignee: Gamblit Gaming, LLC
    Inventors: Mark Paulik, Edvard Toth